Lenvatinib plus PD-1 inhibitor improves survival versus bevacizumab plus PD-1 inhibitor in unresectable hepatocellular carcinoma
Meta-analysis shows lenvatinib-based regimens improve survival for unresectable liver cancer in East Asia
This systematic review and meta-analysis evaluated first-line treatment for unresectable hepatocellular carcinoma in East Asian populations.
A meta-analysis of East Asian patients with unresectable liver cancer found lenvatinib-based regimens improved survival compared to bevacizu…
Network meta-analysis finds similar overall survival for three HCC regimens
Three drugs show similar survival for unresectable liver cancer patients
A network meta-analysis of 11 studies in unresectable hepatocellular carcinoma found no statistically significant differences in overall sur…
Three drugs show similar survival for unresectable liver cancer patients, offering patients clearer choices without proving one option is de…
Combination immunotherapy and targeted therapy regimens show favorable survival outcomes versus monotherapies in unresectable hepatocellular carcinoma
New Data Reveals Which Liver Cancer Treatments Work Best Over Time
This systematic review and pooled analysis of parametric survival curves from 15 randomized controlled trials evaluated first-line treatment…
This research shows that combining two different cancer drugs helps patients live longer than using just one, but the benefit isn't constant…
HBV-positive status linked to higher surgical conversion in unresectable HCC receiving triple therapy
HBV-positive linked to better outcomes in liver cancer triple therapy
This single-center retrospective cohort study evaluated triple therapy with TACE, lenvatinib, and PD-1 inhibitors in 190 patients with initi…
In unresectable liver cancer, triple therapy with TACE, lenvatinib, and PD-1 inhibitors worked better in HBV-positive patients, a small retr…
Triple therapy with TACE, TKIs, and ICIs shows survival benefits in unresectable hepatocellular carcinoma
Triple therapy offers a 52% chance of living three years with advanced liver cancer
This retrospective cohort study evaluated 270 patients with unresectable hepatocellular carcinoma receiving first-line triple therapy across…
Patients with advanced liver cancer receiving triple therapy had a 52% chance of surviving three years, offering new hope for those facing d…
TACE plus donafenib and camrelizumab shows improved outcomes in unresectable hepatocellular carcinoma
Liver Cancer Patients May Live Twice as Long With New Combo
This single-center retrospective cohort study compared TACE plus donafenib and camrelizumab to TACE plus donafenib alone in 116 patients wit…
A new combination therapy could nearly double survival time for advanced liver cancer patients.
TACE plus camrelizumab and rivoceranib prolongs progression-free survival versus TACE alone in unresectable HCC
Combination therapy extends time without cancer progression in liver cancer patients
This phase II randomized trial in 200 patients with unresectable hepatocellular carcinoma compared TACE plus camrelizumab and rivoceranib (T…
Adding two new drugs to standard liver cancer treatment helped patients go 10.8 months longer without their cancer getting worse compared to…
Research across Hepatocellular Carcinoma
Related studies from across the Hepatocellular Carcinoma family.
Dioscin shows therapeutic potential for various liver disorders including MASLD and hepatocellular carcinoma
Plant Compound Dioscin Shows Promise For Liver Disease
This systematic review evaluates the hepatoprotective effects and pharmacokinetics of Dioscin in various liver diseases. The review conclude…
A plant compound called Dioscin may help protect the liver, but human evidence is still missing and high doses carry risks.
MRI-based radiomics models achieve 0.91 AUC for predicting GPC3 expression in hepatocellular carcinoma
MRI Radiomics Models Predict GPC3 Expression in Liver Cancer
This meta-analysis of 7 retrospective studies evaluated the diagnostic accuracy of MRI-based radiomics for predicting GPC3 expression in 1,2…
New MRI-based radiomics models show high accuracy in predicting GPC3 expression, offering a noninvasive way to identify patients for targete…
Gut microbiome composition correlates with clinical outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors
Gut bacteria may influence how liver cancer patients respond to treatment
This meta-analysis of 13 papers examines the relationship between gut microbiota and clinical outcomes in patients with intermediate-to-adva…
Specific types of gut bacteria are linked to how well liver cancer patients respond to immune-based therapies.
Triple Combination Therapy Improves Progression-Free Survival in Patients with Hepatocellular Carcinoma
Trial shows STRIDE plus lenvatinib improves progression-free survival for HCC
A Phase 3 trial demonstrates that combining tremelimumab, durvalumab, and lenvatinib with TACE significantly extends progression-free surviv…
A new combination of drugs and TACE treatment may extend the time before liver cancer progresses for patients with hepatocellular carcinoma.
Bidirectional crosstalk between hepatic stellate cell-derived CAFs and T cells drives immune evasion in HCC
Cell Communication May Drive Immune Resistance in Liver Cancer
This systematic review examines the bidirectional crosstalk between hepatic stellate cell-derived cancer-associated fibroblasts (CAFs) and T…
New research highlights how specific cells in the liver create a protective shield for tumors, making it harder for the immune system to fig…
Post-translational modifications drive drug resistance in hepatocellular carcinoma, systematic review finds
Chemical Changes in Proteins May Help Overcome Drug Resistance in Liver Cancer
This systematic review synthesizes evidence that post-translational modifications (PTMs), including phosphorylation, ubiquitination, acetyla…
Scientists are looking at how specific chemical changes to proteins can help doctors fight liver cancer that does not respond well to standa…
Metabolic risk factors including diabetes and metabolic syndrome are associated with increased hepatocellular carcinoma risk
Metabolic risk factors linked to higher liver cancer risk
This meta-analysis of cohort studies involving more than 45 million participants identifies significant associations between metabolic risk …
New data from over 45 million people show that conditions like diabetes and high blood pressure are linked to a higher risk of liver cancer.
Radiomic Features Demonstrate High Diagnostic Accuracy for Predicting Ki-67 Expression in Hepatocellular Carcinoma
Radiomic Features Help Predict Ki-67 Levels in Liver Cancer
Meta-analysis of 1,708 patients shows radiomic features provide high sensitivity and specificity for predicting Ki-67 expression in HCC.
New data shows that radiomic features can accurately predict Ki-67 expression levels in patients with hepatocellular carcinoma.
Immune Health Index serves as a protective prognostic factor in post-resection hepatocellular carcinoma
New immune health index helps predict liver cancer outcomes
This meta-analysis evaluates the Immune Health Index (IHI) and its clinical version (cIHI_v8) for prognostic stratification in patients with…
A new tool called the Immune Health Index helps doctors predict how well patients with liver cancer might respond to immunotherapy.
NRF2 signaling promotes tumor cell survival and multidrug resistance in advanced hepatocellular carcinoma
NRF2 Pathway Shows Complex Roles in Liver Cancer Growth
This systematic review synthesizes the role of NRF2 signaling in hepatocellular carcinoma, highlighting its dual role in early injury protec…
The NRF2 pathway acts as a double-edged sword in liver cancer, protecting early cells but helping advanced tumors survive and resist treatme…
PD-(L)1 plus VEGF monoclonal antibody shows most favorable overall survival in advanced hepatocellular carcinoma
New data identifies best immunotherapy combinations for advanced liver cancer
This meta-analysis of 15 phase III trials evaluated first-line immunotherapy combinations for advanced hepatocellular carcinoma. The analysi…
A large review of over 9,000 patients reveals which drug combinations offer the best survival rates and safety for advanced liver cancer.
Durvalumab plus tremelimumab median PFS was 5.4 months in HIMALAYA eligible patients
Patients meeting specific criteria live longer with liver cancer treatment
This observational study of 412 patients with unresectable hepatocellular carcinoma found that those meeting HIMALAYA trial eligibility had …
A study of 412 patients shows those meeting certain health criteria lived significantly longer when treated for advanced liver cancer.
Questions about Unresectable Hepatocellular Carcinoma
Does adding camrelizumab improve outcomes for unresectable hepatocellular carcinoma patients?
Adding camrelizumab to standard treatments like TACE and targeted drugs significantly improves tumor response, disease control, and survival times for patients with unresectable hepatocellular carcinoma.
Full answer →Can triple therapy help patients with unresectable hepatocellular carcinoma live longer?
Yes, triple therapy (TACE plus targeted drugs and immunotherapy) can help patients with unresectable hepatocellular carcinoma live longer, with studies showing improved overall survival and progression-free survival compared to TACE alone or double therapy.
Full answer →Does having HBV make surgery more likely for unresectable hepatocellular carcinoma?
Having hepatitis B virus (HBV) infection is linked to a higher chance of surgical conversion for patients with unresectable hepatocellular carcinoma treated with triple therapy.
Full answer →